Recent Updates
Recently added Catalysts
OVID Positive Sentiment

Rare Epilepsy Network

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Rare Epilepsy Network (REN) is a collaborative initiative involving the Epilepsy Foundation, IFCR, RTI International, Columbia University, and various organizations. It aims to support patients with rare syndromes related to epilepsy or seizures. This partnership seeks to enhance awareness and representation for affected individuals.
Price reaction · baseline $3.54 (2023-09-22T16:30:00.000Z) · hit during market hours · 20 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+2.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration among multiple reputable organizations
  • Focus on rare syndromes associated with epilepsy
  • Potential for improved patient representation and support

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

The Rare Epilepsy Network, or REN for short, is a collaboration between the Epilepsy Foundation, the IFCR, RTI international, Columbia University, and many different organizations that represent patients with a rare syndrome or disorder that is associated with epilepsy or seizures.
Visit Site »

Frequently Asked Questions

What is the Rare Epilepsy Network?

The Rare Epilepsy Network (REN) is a collaboration focused on rare epilepsy syndromes.

Which organizations are involved in REN?

REN includes the Epilepsy Foundation, IFCR, RTI International, and Columbia University.

What is the goal of the Rare Epilepsy Network?

The goal is to enhance support and representation for patients with rare epilepsy disorders.

ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Rare Epilepsy Network epilepsy seizures patient support collaboration
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →